Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RXI-185
- Development stage
- Preclinical
- Lead developer
- Phio Pharmaceuticals
- Modality
- Small Molecules, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Topical, Intradermal
01
Overview
RXI-185 is a self-delivering small interfering RNA (siRNA) compound developed by Phio Pharmaceuticals. It specifically targets and silences the expression of matrix metalloproteinase-1 (MMP1), an enzyme involved in the breakdown of collagen in the skin. By inhibiting MMP1, RXI-185 aims to slow or prevent ultraviolet radiation (UVR)-induced collagen degradation, thereby improving or slowing the progression of skin thickening, loss of elasticity, and wrinkles associated with photo-aging and other age-related skin disorders. The compound utilizes Phio’s proprietary INTASYL siRNA gene silencing technology, which allows for efficient cellular uptake without specialized delivery vehicles. RXI-185 is being developed primarily as a cosmetic ingredient for improving the appearance of wrinkles and skin laxity but may also have potential pharmaceutical applications in dermatology[1][2][3][5].
- Other names
- TGFB1 sd-rxRNATGFB-1 sd-rxRNATGFB 1 sd-rxRNAINTASYL TGFB1
02
Targets
MMP1 (Matrix metalloproteinase-1)
Beyond the preview
Go deeper on RXI-185.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RXI-185.